Oruka Therapeutics, Inc. (ORKA)
Automate Your Wheel Strategy on ORKA
With Tiblio's Option Bot, you can configure your own wheel strategy including ORKA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Oruka Therapeutics: A Potential Future Psoriasis Play
Published: February 25, 2026 by: Seeking Alpha
Sentiment: Positive
Oruka Therapeutics, Inc. has surged after ORKA-001 showed a half-life four times Skyrizi in Phase 1, targeting the $30B psoriasis market. ORKA-001 and ORKA-002 aim for best-in-class efficacy with dramatically less frequent dosing, potentially shifting the treatment paradigm for chronic skin diseases. Phase 2a EVERLAST-A results for ORKA-001 are expected in 2H26; meaningful revenue is not anticipated until 2031, highlighting ORKA stock's long-term, high-risk profile.
Read More
Oruka Therapeutics to Present at Multiple November Investor Conferences
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:
Read More
Oruka Therapeutics Announces $180 Million Private Placement
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $180 million to the Company, before placement agent fees and offering expenses. The PIPE financing was led by Viking Global Investors, and included participation from both new and existing investors, …
Read More
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorable safety profile consistent with the IL-23p19 class EVERLAST-A Phase 2a trial enrollment ongoing with data expected 2H 2026 MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced interim data from its Phase 1 trial of ORKA-001, …
Read More
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026
Read More
Oruka Therapeutics to Present at Multiple March Investor Conferences
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:
Read More
About Oruka Therapeutics, Inc. (ORKA)
- IPO Date 1997-08-08
- Website http://www.orukatx.com
- Industry Biotechnology
- CEO Lawrence Otto Klein
- Employees 28